Dr. Reddy' Labs launches Ziprasidone Mesylate injection in US market
Mumba/UNI: Pharma major Dr Reddy's Labs on Tuesday announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/ml Single-dose Vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/ml, approved by the US Food and Drug Administration (USFDA).
"We are pleased to bring the first generic of Ziprasidone Mesylate for injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy," explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy's Laboratories.
This is a great addition to our injectable offering in the US market as we continue to augment our portfolio and drive growth within the hospital segment."
The Geodon brand had US sales of approximately USD21.8 million MAT for the most recent twelve months ending in January 2020, according to IQVIA Health.
(Image Credit: Wikimedia Commons)
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
